Cancer Research Technology
Log in Register
Menu

IDH1 Mutant Glioma Xenograft (JHH-273) mouse

Info

Catalogue Number 156429
Antigen/Gene or Protein Targets IDH1
Disease Keywords Glial tumor formation
Relevance An in vivo Isocitrate Dehydrogenase (IDH-1) glioma mouse xenograft model has been developed to further study effective therapies for IDH mutations characterized by increased DNA methylation and production of the common oncometabolite, 2-HG. Difficult grafting cell-culture techniques and current engineered cell line quality have limited additional laboratory studies; however, this model was developed directly from a WHO grade III- glial cell positive cancer patient tissue (JHH273) with a confirmed IDH mutation through DNA sequencing and maintains IDH-1 mutation features observed in human primary glial brain tumors. Additionally, when models were exposed to a demethlyating agent, 5-azacytidine, a reduction in methylation and tumor growth was observed opening the door for more clinical analysis. This model meets a critical need to test drug agents targeting mechanisms involved in glial tumor formation.
Growth/Phenotype Keywords 4–6-week old female athymic nude mice
Mouse Genetic Background/Cross History 4–6-week old female athymic nude mice
Research Area Cancer, Drug Discovery & Development

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Borodovsky et al. 2013. Oncotarget. 4(10):1737-47. PMID: 24077805.


Add a reference

References: 1 entry

Borodovsky et al. 2013. Oncotarget. 4(10):1737-47. PMID: 24077805.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor